Flow cytometric determination of the frequency and heterogeneity of expression of human melanoma-associated antigens.

We used flow cytometry to measure the expression of human melanoma antigens on cell suspensions dissociated from metastatic masses. The objective was to study the heterogeneity between tumor samples from different patients and between different tumors excised from a single patient. Fifty-three metastases excised from 34 melanoma patients were analyzed with a panel of nine murine monoclonal antibodies (MOABs). Melanoma cells were stained by an indirect fluorescent method and analyzed on a Coulter EPICS C flow cytometer after gating to exclude tumor-infiltrating leukocytes and dead cells. The most consistently and most strongly expressed antigen was the high-molecular-weight proteoglycan (detected by the MOAB 9.2.27), which was expressed on 95% of the melanoma specimens and by a high proportion of cells within each specimen (mean +/- SE, 79.2 +/- 5.5). However, strong expression of this antigen was limited to melanoma cells that had been dissociated mechanically and was markedly diminished by exposure to collagenase. Culture of collagenase-dissociated tumor cells for 24 to 48 h resulted in reexpression of the antigen. The expression of other melanoma-associated antigens was not affected by collagenase treatment, but for these antigens there was more variability between cells from an individual tumor and between tumors from different patients. The percentage of enzyme-dissociated tumors considered positive for MOAB binding (defined as at least 10% of cells positive) and the mean +/- SE of the percentage of positive cells within a tumor were as follows: MOAB ME-9-61 (antigen, p97) = 84% + (41.2 +/- 5.4%); MOAB ME-20.4 (antigen, nerve growth factor receptor) = 40% + (18.7 +/- 5.1%); MOAB ME-24 (antigen, ganglioside GD3) = 84% + (50.8 +/- 4.8%); MOAB ME-311 (antigen, ganglioside 9-O-acetyl-GD3) = 76% + (42.5 +/- 5.1%); MOAB ME-361 (antigen, mainly ganglioside GD2) = 3% + (1.9 +/- 0.8%); MOAB 3F8 (antigen, ganglioside GD2) = 36% (10.5 +/- 3.8%); MOAB 14G2a (antigen, ganglioside GD2) = 86% + (46.0 +/- 6.7%); MOAB L243 (antigen, HLA-DR) = 56% + (22.5 +/- 5.5%). In 19 cases, we were able to compare the antigenic profiles of two tumors excised from the same patient at different times. Analysis by nonindependent t test showed no significant differences in MOAB binding between the paired tumors. Moreover, linear regression analysis indicated that there was a linear relationship, with a slope approximately = 1, between the percentage of positive cells in Tumor 1 versus Tumor 2.(ABSTRACT TRUNCATED AT 400 WORDS)

[1]  T. Kipps,et al.  Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. , 1989, Cancer research.

[2]  D. Berd,et al.  Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide. , 1988, Cancer investigation.

[3]  R. Saxton,et al.  Gangliosides of human melanoma , 1989, Cancer.

[4]  R. Saxton,et al.  Gangliosides of human melanoma: altered expression in vivo and in vitro. , 1987, Cancer research.

[5]  D. Elder,et al.  Monoclonal antibody-defined correlations in melanoma between levels of GD2 and GD3 antigens and antibody-mediated cytotoxicity. , 1987, Cancer research.

[6]  W. Clark,et al.  GD2 ganglioside biosynthesis is a distinct biochemical event in human melanoma tumor progression , 1986, FEBS letters.

[7]  H. Maguire,et al.  Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. , 1986, Cancer research.

[8]  K. Mujoo,et al.  Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins , 1986, The Journal of cell biology.

[9]  R. Schroff,et al.  Human melanoma-associated antigens: analysis of antigenic heterogeneity by molecular, serologic and flow-cytometric approaches. , 1986, Molecular immunology.

[10]  D. Elder,et al.  Proton NMR and fast-atom bombardment mass spectrometry analysis of the melanoma-associated ganglioside 9-O-acetyl-GD3. , 1985, The Journal of biological chemistry.

[11]  S. Ferrone,et al.  Heterogeneous expression of melanoma-associated antigens and HLA antigens by primary and multiple metastatic lesions removed from patients with melanoma. , 1985, Cancer research.

[12]  N. Cheung,et al.  Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. , 1985, Cancer research.

[13]  Herbert C. Hoover,et al.  Prospectively randomized trial of adjuvant active‐specific immunotherapy for human colorectal cancer , 1985 .

[14]  R. Klevecz,et al.  Cell‐cycle‐dependent expression of human melanoma membrane antigen analyzed by flow cytometry , 1985, Cancer.

[15]  K. Foon,et al.  Intratumor localization of monoclonal antibody in patients with melanoma treated with antibody to a 250,000-dalton melanoma-associated antigen. , 1985, Journal of the National Cancer Institute.

[16]  D. Elder,et al.  Characterization of nerve growth factor receptor in neural crest tumors using monoclonal antibodies. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[17]  T. Lindmo,et al.  Stable quantitative differences of antigen expression in human melanoma cells isolated by flow cytometric cell sorting , 1984, International journal of cancer.

[18]  A. Varki,et al.  O-acetylation of disialoganglioside GD3 by human melanoma cells creates a unique antigenic determinant. , 1984, Science.

[19]  A. Varki,et al.  A monoclonal antibody recognizes an O-acylated sialic acid in a human melanoma-associated ganglioside. , 1984, The Journal of biological chemistry.

[20]  M. Herlyn,et al.  Identification of melanoma-associated antigens using fixed tissue screening of antibodies. , 1984, Cancer research.

[21]  R. Reisfeld,et al.  Characterization of monoclonal antibody 155.8 and partial characterization of its proteoglycan antigen on human melanoma cells. , 1984, Journal of immunology.

[22]  E. Rofstad,et al.  Antigen expression in human melanoma cells in relation to growth conditions and cell‐cycle distribution , 1984, International journal of cancer.

[23]  W. Clark,et al.  Production and characterization of monoclonal antibodies against human malignant melanoma. , 1983, Cancer investigation.

[24]  S. Ferrone,et al.  Heterogeneity of HLA-A,B, Ia-like, and Melanom Expression by Human Melanoma Cell Lines Analyzed with Monoclonal Antibodies and Flow Cytometry , 1982 .

[25]  R. Reisfeld,et al.  Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[26]  S. Burchiel,et al.  Heterogeneity of HLA-A,B, Ia-like, and melanoma-associated antigen expression by human melanoma cell lines analyzed with monoclonal antibodies and flow cytometry. , 1982, Cancer research.

[27]  A. Houghton,et al.  Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens , 1981, The Journal of experimental medicine.

[28]  D. Galloway,et al.  Production and characterization of monoclonal antibody to a melanoma specific glycoprotein. , 1981, Hybridoma.

[29]  J. Brown,et al.  Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[30]  W. Clark,et al.  Specific immunoreactivity of hybridoma-secreted monoclonal anti-melanoma antibodies to cultured cells and freshly derived human cells. , 1980, Cancer research.

[31]  M. Hanna,et al.  Preparation of immunotherapeutic autologous tumor cell vaccines from solid tumors. , 1979, Cancer research.